VIRIDIAN THERAPEUTICS ORS INC (VRDN)
Health Care · Rare autoimmune disease biopharmaceuticals · NASDAQ
Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and autoimmune diseases, with lead candidate veligrotug advancing through late-stage trials against Amgen's Tepezza.
What VIRIDIAN THERAPEUTICS ORS INC does
Viridian Therapeutics is a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare autoimmune and rare diseases. The company is advancing a pipeline of product candidates including anti-IGF-1R therapies (veligrotug and elegrobart) for thyroid eye disease (TED), FcRn inhibitors for multiple autoimmune disorders, and a TSHR inhibitor program for TED and Graves' disease. The company is building commercial infrastructure and preparing for the anticipated launch of its first commercial product.
Themes: ["Thyroid eye disease (TED) treatment","Autoimmune rare diseases","IGF-1R inhibitors","Monoclonal antibodies","Biopharmaceutical development"]
Fundamentals
- Price$20.20 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return+18.5% as of 2026-07-09 close
- Net margin-508.5% as of 2026-07-10
- Gross margin+2.4% as of 2026-07-10
- ROE-60.7% as of 2026-07-10
- Debt / equity0.14 as of 2026-07-10
- Revenue growth (YoY)+23382.8% as of 2026-07-10
- Revenue CAGR (3y)-2.5% SEC XBRL
- Beta0.93 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory risk: veligrotug's Phase 3 programs (THRIVE and THRIVE-2) must achieve regulatory approval; delays or negative outcomes could delay or prevent commercial launch","Competition from established therapies: Amgen's Tepezza (teprotumumab) is the only FDA-approved medicine for TED and is expanding geographically; commercial success depends on differentiation and market acceptance of veligrotug and elegrobart","Commercial readiness and execution: Company is transitioning from pre-commercial to commercial stage; building sales, marketing, and patient services infrastructure carries execution risk and substantial capital requirements"]
Competitors & peers
- Amgen (AMGN) – markets Tepezza (teprotumumab), the only FDA-approved medicine for TED
- Roche
- Regeneron Pharmaceuticals
- AstraZeneca
- Eli Lilly
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.